Aelium

Aelis Farma is a clinical-stage biotechnology company focused on developing a new class of drugs known as Signaling-Specific Inhibitors (SSi) of the CB1 receptor. These compounds are designed to selectively inhibit the pathological overactivation of the CB1 receptor without interfering with its normal physiological functions, potentially avoiding the side effects associated with traditional antagonists. The company's lead candidate, AEF0117, is currently in Phase 2b clinical trials for the treatment of cannabis use disorder. A second candidate, AEF0217, is being developed to treat cognitive disorders, including those associated with Down Syndrome. Aelis Farma aims to address significant unmet medical needs in brain disorders through its innovative pharmacological approach.